相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy
Douaa Sayed et al.
LEUKEMIA RESEARCH (2014)
The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledgebase of drug targets and their ligands
Adam J. Pawson et al.
NUCLEIC ACIDS RESEARCH (2014)
Differences in structural elements of Bcr-Abl oncoprotein isoforms in Chronic Myelogenous Leukemia
Abdul Hai et al.
BIOINFORMATION (2014)
THE CONCISE GUIDE TO PHARMACOLOGY 2013/14: ENZYMES
Stephen P. H. Alexander et al.
BRITISH JOURNAL OF PHARMACOLOGY (2013)
Effects of plerixafor in combination with BCR-ABL kinase inhibition in a murine model of CML
Anupriya Agarwal et al.
BLOOD (2012)
EGCG Inhibits Transforming Growth Factor-β-Mediated Epithelial-to-Mesenchymal Transition via the Inhibition of Smad2 and Erk1/2 Signaling Pathways in Nonsmall Cell Lung Cancer Cells
Liang-Chih Liu et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2012)
EGCG Enhances the Therapeutic Potential of Gemcitabine and CP690550 by Inhibiting STAT3 Signaling Pathway in Human Pancreatic Cancer
Su-Ni Tang et al.
PLOS ONE (2012)
Role of STAT3 in transformation and drug resistance in CML
Rajesh R. Nair et al.
FRONTIERS IN ONCOLOGY (2012)
Green tea polyphenol EGCG suppresses lung cancer cell growth through upregulating miR-210 expression caused by stabilizing HIF-1α
Hong Wang et al.
CARCINOGENESIS (2011)
Epigallocatechin-3-gallate (EGCG) downregulates EGF-induced MMP-9 in breast cancer cells: involvement of integrin receptor α5β1 in the process
Triparna Sen et al.
EUROPEAN JOURNAL OF NUTRITION (2011)
Green tea polyphenol EGCG blunts androgen receptor function in prostate cancer
Imtiaz A. Siddiqui et al.
FASEB JOURNAL (2011)
Epigallocatechin-3-gallate (EGCG) for Clinical Trials: More Pitfalls than Promises?
Derliz Mereles et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2011)
16-Hydroxycleroda-3,13-dien-15,16-olide regulates the expression of histone-modifying enzymes PRC2 complex and induces apoptosis in CML K562 cells
Yi-Hsiung Lin et al.
LIFE SCIENCES (2011)
CML: Evolution and design
Peter Murray-Rust et al.
JOURNAL OF CHEMINFORMATICS (2011)
Guidelines for reporting experiments involving animals: the ARRIVE guidelines
J. C. McGrath et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Animal research: Reporting in vivo experiments: The ARRIVE guidelines
Carol Kilkenny et al.
BRITISH JOURNAL OF PHARMACOLOGY (2010)
Modulation of Akt and ERK1/2 Pathways by Resveratrol in Chronic Myelogenous Leukemia (CML) Cells Results in the Downregulation of Hsp70
Soumyajit Banerjee Mustafi et al.
PLOS ONE (2010)
Chronic Myeloid Leukemia and Second-Generation Tyrosine Kinase Inhibitors: When, How, and Which One?
Elias Jabbour et al.
SEMINARS IN HEMATOLOGY (2010)
The Green Tea Polyphenol EGCG Potentiates the Antiproliferative Activity of c-Met and Epidermal Growth Factor Receptor Inhibitors in Non-small Cell Lung Cancer Cells
Shawn A. Milligan et al.
CLINICAL CANCER RESEARCH (2009)
Preparation and Antioxidant Activity of Green Tea Extract Enriched in Epigallocatechin (EGC) and Epigallocatechin Gallate (EGCG)
Jianhui Hu et al.
JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY (2009)
Enhanced antitumor activities of (-)-epigallocatechin-3-O-gallate fatty acid monoester derivatives in vitro and in vivo
Kazuaki Matsumura et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Confluence-induced cell cycle exit involves pre-mitotic CDK inhibition by p27Kip1 and cyclin D1 downregulation
Anne-Amandine Chassot et al.
CELL CYCLE (2008)
Tyrosine phosphatase SHP-2 is a regulator of p27Kip1 tyrosine phosphorylation
Irini Tossidou et al.
CELL CYCLE (2008)
Decreased expression level of SH2 domain-containing protein tyrosine phosphatase-I (ShpI) is associated with progression of chronic myeloid leukaemia
H. M. Amin et al.
JOURNAL OF PATHOLOGY (2007)
The ρ-kinase inhibitors Y-27632 and fasudil act synergistically with imatinib to inhibit the expansion of ex vivo CD34+ CML progenitor cells
J. Burthem et al.
LEUKEMIA (2007)
Role of curcumin in cancer therapy
Shishir Shishodia et al.
CURRENT PROBLEMS IN CANCER (2007)
SHP-2 phosphatase is required for hematopoietic cell transformation by Bcr-Abl
Jing Chen et al.
BLOOD (2007)
Loss of SHP1 enhances JAK3/STAT3 signaling and decreases proteosome degradation of JAK3 and NPM-ALK in ALK+ anaplastic large-cell lymphoma
Yajun Han et al.
BLOOD (2006)
Restoration of shp1 expression by 5-AZA-2′-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma
Y. Han et al.
LEUKEMIA (2006)
BCR-ABL activates STAT3 via JAK and MEK pathways in human cells
Paul Coppo et al.
BRITISH JOURNAL OF HAEMATOLOGY (2006)
Intermittent dosage of imatinib mesylate in CML patients with a history of significant hematologic toxicity after standard dosing
Edgar Faber et al.
LEUKEMIA & LYMPHOMA (2006)
Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML)
C Walz et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2006)
Transient or long-term silencing of BCR-ABL alone induces cell cycle and proliferation arrest, apoptosis and differentiation
J Rangatia et al.
LEUKEMIA (2006)
EGCG inhibits activation of the insulin-like growth factor-1 receptor in human colon cancer cells
M Shimizu et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Expression of cell cycle associated proteins cyclin A, CDK-2, p27kip1 and p53 in equine sarcoids
C Nixon et al.
CANCER LETTERS (2005)
Identification of mcl-1 as a BCR/ABL-dependent target in chronic myeloid leukemia (CML):: evidence for cooperative antileukemic effects of imatinib and mcl-1 antisense oligonucleotides
KJ Aichberger et al.
BLOOD (2005)
Essential role of caspases in epigallocatechin-3-gallate-mediated inhibition of nuclear factor kappaB and induction of apoptosis
S Gupta et al.
ONCOGENE (2004)
VEGF receptor phosphorylation status and apoptosis is modulated by a green tea component, epigallocatechin-3-gallate (EGCG), in B-cell chronic lymphocytic leukemia
YK Lee et al.
BLOOD (2004)
A major constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell line, CaSki cells, through apoptosis, G1 arrest, and regulation of gene expression
WS Ahn et al.
DNA AND CELL BIOLOGY (2003)
Inhibition of the Bcr-Abl tyrosine kinase as a therapeutic strategy for CML
BJ Druker
ONCOGENE (2002)
Anti-proliferative and differentiation-inducing activities of the green tea catechin epigallocatechin-3-gallate (EGCG) on the human eosinophilic leukemia EoL-1 cell line
HL Lung et al.
LIFE SCIENCES (2002)
Role of the tyrosine phosphatase SHP-1 in K562 cell differentiation
B Bruecher-Encke et al.
LEUKEMIA (2001)
BCR/ABL inhibition by an escort/phosphatase fusion protein
YM Lim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
分享论文
